|Articles|September 17, 2019

Elligo Health Research Partners with Jack Nathan Health

Elligo Health Research, a healthcare-enabling research organization, is helping Jack Nathan Health patients gain access to clinical research as a care option at its Canadian Walmart clinics. Jack Nathan Health operates physician-led medical practices that accommodate clinic appointments, lab services, physiotherapy and chiropractic services, and more.  

“We take our commitment to exceptional service and care seriously,” said George Barakat, CEO at Jack Nathan Health. “Partnering with Elligo gives us the opportunity to stay informed of the newest advancements, improve our cutting-edge facilities, and continue to meet our patients’ healthcare challenges.”

This partnership expands Elligo’s Research Ready site network to include healthcare experts and their patients from across. Jack Nathan Health patients who qualify for a research study will be given the opportunity to receive treatment through Elligo’s Goes Direct approach, which connects drug development companies to a diverse pool of patients.

“To date, this is our greatest achievement in our mission to connect research to patients,” said John Potthoff, PhD, CEO of Elligo.


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.